Skip to content
6-K

Foreign Interim / Material

Nasus Pharma Ltd NSRX

0001493152-25-029210

← back to feed
Filed
Dec 29, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q2 2025 · Jun 30, 2025 7.36M sh
Shares Diluted Q2 2025 · Jun 30, 2024 6.89M sh
Operating Cash Flow Q2 2025 · Jun 30, 2025 −$433K
Operating Cash Flow Q2 2025 · Jun 30, 2024 −$180K
Cash And Equivalents Q2 2025 · Jun 30, 2025 $203K
Cash And Equivalents Q2 2025 · Dec 31, 2024 $284K
Cash And Equivalents Q2 2025 · Jun 30, 2024 $900K
Stockholders Equity Q2 2025 · Jun 30, 2025 −$4.31M
Stockholders Equity Q2 2025 · Dec 31, 2024 −$3.21M
Stockholders Equity Q2 2025 · Jun 30, 2024 −$4.66M
Stockholders Equity Q2 2025 · Dec 31, 2023 −$3.8M
Current Liabilities Q2 2025 · Jun 30, 2025 $4.95M
Current Liabilities Q2 2025 · Dec 31, 2024 $3.93M
Total Liabilities Q2 2025 · Jun 30, 2025 $4.95M
Total Liabilities Q2 2025 · Dec 31, 2024 $3.93M
Current Assets Q2 2025 · Jun 30, 2025 $291K
Current Assets Q2 2025 · Dec 31, 2024 $457K
Total Assets Q2 2025 · Jun 30, 2025 $639K
Total Assets Q2 2025 · Dec 31, 2024 $717K
Eps Diluted Q2 2025 · Jun 30, 2025 −$0.17
Eps Diluted Q2 2025 · Jun 30, 2024 −$0.13
Eps Basic Q2 2025 · Jun 30, 2025 −$0.17
Eps Basic Q2 2025 · Jun 30, 2024 −$0.13
Sga Expense Q2 2025 · Jun 30, 2025 $528K
Sga Expense Q2 2025 · Jun 30, 2024 $315K
Rd Expense Q2 2025 · Jun 30, 2025 $289K
Rd Expense Q2 2025 · Jun 30, 2024 $168K
Net Income Q2 2025 · Jun 30, 2025 −$1.25M
Net Income Q2 2025 · Jun 30, 2024 −$871K
Operating Income Q2 2025 · Jun 30, 2025 −$817K
Operating Income Q2 2025 · Jun 30, 2024 −$483K